MSC Therapy for Alzheimer’s Disease: Clinical Trial Data on Laromestrocel and Biomarker Outcomes
Recent Phase 2a clinical trials demonstrate that mesenchymal stem cell therapy can slow brain atrophy by up to 62% and reduce neuroinflammation in mild Alzheimer's patients. Review of laromestrocel trial data, biomarker outcomes, and emerging treatment options.